Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

MISSISSAUGA, ON, April 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the three months ended February 29, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At February 29, 2008, our cash and cash equivalents totaled $19.9 million, compared with $23.5 million at November 30, 2007.

We incurred a net loss for the three months ended February 29, 2008, of $5.3 million, or $0.24 per common share, compared with a net loss of $7.7 million, or $0.47 per common share for the same period in 2007. A key driver of this decrease was a $1.6 million reduction in expenses resulting from the repayment of the senior convertible notes in April 2007, and lower infrastructure and other support costs driven by lower employee numbers in 2008.

For the three months ended February 29, 2008, research and development expenses decreased to $2.8 million from $3.0 million for the comparable period in 2007. During the first quarter of 2008, these costs were incurred for the initial commercialization of Celacade in Europe and for preparations for ACCLAIM II, a study designed to evaluate the Celacade technology for the treatment of patients with NYHA Class II heart failure.

General and administration expenses were $2.7 million for the three months ended February 29, 2008, compared to $3.6 million for the same period in 2007 as a result of lower employee numbers.

Highlights

- In January, preclinical findings demonstrating that VP025, the lead

candidate from our VP series of drugs, provides a significant

neuroprotective effect in a model of Parkinson's disease were

published in the European Jou
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... The J. R. Simplot Company,s Plant Sciences ... for improving crops, leading to new, better and ...   Innate™ Technology is a patented ... own genes to enhance desirable traits and to ...
... SUNNYVALE, Calif., July 12, 2011 Molecular Devices ... discovery & development, life science research, and bioassay/test ... functionality of the SoftMax® Pro Software and prominence ... control ability via an Apple iPad wireless device. ...
... New research from the Trudeau Institute may help to ... lives of patients with sepsis. The study was led by ... shows that fibrin, a key product of the blood clotting ... , a gram-negative bacterium that causes sepsis in humans and ...
Cached Biology Technology:Molecular Devices Enables Intuitive Functionality at Your Fingertips on the Apple iPad with the Latest SoftMax Pro Software 2Trudeau Institute announces a discovery in the fight against sepsis 2
(Date:4/20/2014)... Most drugs used to treat lung, breast and pancreatic ... Researchers at the University of California, San Diego School ... CD61 on the surface of drug-resistant tumors that appears ... cell-like properties of cancer cells. , The findings, ... Nature Cell Biology , may point to new ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... Hormone replacement therapies, or medications containing female hormones ... body, are often prescribed to reduce the effects ... women. Research and clinical trials on hormone replacement ... especially breast cancer, in post-menopausal women who take ...
... been elected as a fellow of the American ... organization,s Council on Basic Cardiovascular Sciences., Nguyen, who ... 2005, specializes in cellular engineering. Her research also ... therapies., Liping Tang, interim chairman of the UT ...
... Houser, PhD, FAHA, Director of the Cardiovascular Research Center ... studying the heart for nearly three and a half ... to cardiovascular research, work that led to his recent ... Association (AHA) the Basic Cardiovascular Science (BCVS) Council ...
Cached Biology News:Women prescribed combination HRT should use caution when taking apigenin supplement, MU study finds 2Temple's Dr. Steven Houser recognized by the American Heart Association 2Temple's Dr. Steven Houser recognized by the American Heart Association 3
Polio component type I...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
... comprehensive microarray service for systematic discovery ... non-coding RNAs (ncRNAs) using a novel ... which enables highly sensitive and specific ... This comprehensive service includes custom probe ...
... LC Sciences provides a comprehensive ... protein kinase substrate (PKS) peptide microarrays ... proteomic scale kinase profiling, quantitative measurement ... discovery research. This comprehensive service includes ...
Biology Products: